含羟基喜树碱联合方案治疗中晚期非小细胞肺癌

目的 :观察含羟基喜树碱 (HCPT)联合方案治疗中晚期非小细胞肺癌 (NSCLC)患者的客观疗效及毒副作用。方法 :4 6例中晚期非小细胞肺癌患者为治疗组 ,应用含羟基喜树碱方案化疗 ,其中 2 5例肺腺癌患者接受HFAP方案 ,2 1例肺鳞癌患者接受HCAP方案 ,4周为一周期 ,2周期为一疗程 ;以同期住院的未用HCPT联合化疗的同类患者 4 2例作为对照组 ,其剂量、周期、疗程与治疗组相同 ,但不用HCPT。结果 :治疗组 4 3例患者完成一疗程治疗 ,肺腺癌有效率为 5 6 % ,CR 2例 ,PR 12例 ;肺鳞癌有效率为 5 5 5 % ,CR为 0 ,PR 10例 ,总有效率 (CR +PR)为 5 5 8% ;对照组 4 2例均完成一疗程治疗 ,肺腺癌有效率为37 5 % ,CR 1例 ,PR 9例 ;肺鳞癌有效率为 33 3% ,PR 6例 ,有效率 35 7% ;两组间差异显著 (P <0 0 5 )。治疗组和对照组的毒副反应主要表现为食欲不振、脱发、恶心呕吐和白细胞及血小板减少 ,两组毒副反应发生率无显著性差异 (P >0 0 5 )。结论 :羟基喜树碱联合化疗治疗中晚期非小细胞肺癌疗效确切 ,副作用可耐受 ,该药是治疗非小细胞肺癌较为有效的药物 ,值得进一步在临床中观察和研究。

Treating middle and advanced-stage non-small cell lung cancer (NSCLC) with joint chemotherapy with hydroxycamptothecin (HCPT)

Objective:To observe the curative eff ect and toxic and side effect of joint chemotherapy with hydroxycamptothecin (HCPT) to treat middle and advanced stage non-small cell lung cancer (NSCLC).Methods:Making 46 patients with middle and advanced stage non-small cell lung cancer (NSCLC) as treating group.Adding HCPT to routine chemot herapy program,among which 25 pulmonary adenocarcinoma patients received HFAP program chemotherapy,and 21 pulmonary squamous carcinoma patients received HCAP program,take 4 weeks as 1 cycle,and 2 cycle as 1 course of treatment.Make the same kinds of 42 patients who were hospitalized at the same time and were not receive d HCPT joint chemotherapy as control group,the dose,cycle,course of treatment of the chemotherapy are all the same with treating group,but HCPT was not given.Results:The 43 patients in treating group had completed 1 course of treatment,the effective rate for pulmonary adenocarcinoma was 56%,among w hich there were 2 case of CR,12 cases PR,and the effective rate for pulmonary s quamous carcinoma was 55.5%,among which CR was 0,PR were 10 cases,the total effe ctive rate (CR+PR) was 55.8%;and there are 42 cases had completed 1 course of tr eatment in control group,the effective rate of pulmonary adenocarcinoma was 37.5 %,among which CR was 1 case,PR are 9 cases;the effective rate of pulmonary squam ous carcinoma was 33.3%,among which CR was 0,PR were 6 cases,the total effective rate (CR+PR) was 35.7%;the difference between two groups was significant (P <0.05).The main manifestation of the toxic and side effects in the treating gro up and control group are anorexia,alopecia,nausea,vomiting,leucocytopenia and th rombocytopenia,and there was no significant discrepancy on the incidence of toxi c and side effecs in the two groups(P>0.05).Conclusion:There are certain curative effect of joint che motherapy with hydroxycamptothecin (HCPT) to treat middle and advanced stage non -small cell lung cancer (NSCLC),and the side effect can be tolerated.HCPT is a fairly effective drug to treat NSCLC,and is worthy of further observation and re search in clinic.